Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Charting, Price Performance, News & Related Contracts.

This highlights the company’s ability to keep up with all of its pipeline programs. However ... Their VK2735 drug is a GLP-1 dual agonist being developed for patients with obesity. During the quarter, ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery ...

GLP-1 supplements are advertised as a cheaper alternative to weight loss with Ozempic or Wegovy. Doctors explain if they help ...

This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...

Each year, the Lasker Awards honor a number of medical professionals doing standout work in research and public service. The ...

Patients prescribed glucagon-like peptide-1 agonists, including Ozepmic and Wegovy, have a significantly higher postoperative infection rate following ankle-fusion procedures, according to a Sept. 20 ...